Bionomics

Bionomics ROE

Delisted

The Return on Equity (ROE) of Bionomics (BNO.AX) as of Sep 27, 2026 is -38.23 %. In the previous year, Return on Equity (ROE) was -18.27 % — a change of 109.24% (lower).

ROE

-38.23 %

YoY

109.24%

Last updated:

In 2026, Bionomics's return on equity (ROE) was -38.23 %, a 109.24% increase from the -18.27 % ROE in the previous year.

The Bionomics ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2015
-53.02 AUD
Jan 1, 2016
-37.57 AUD
Jan 1, 2017
-16.68 AUD
Jan 1, 2018
-147.93 AUD
Jan 1, 2019
-62.80 AUD
Jan 1, 2020
-56.13 AUD
Jan 1, 2021
-18.27 AUD
Jan 1, 2022
-38.23 AUD
The Bionomics ROE history
YEARROEYoY
-38.23 %+109.24%
-18.27 %-67.45%
-56.13 %-10.62%
-62.80 %-57.55%
-147.93 %+786.61%
-16.68 %-55.59%
-37.57 %-29.14%
-53.02 %-840.35%
7.16 %—
Access this data via the Eulerpool API
Get Free API Key

Bionomics Stock analysis

What does Bionomics do? Bionomics Ltd is an Australian biopharmaceutical company specializing in the development of novel therapeutics for the treatment of diseases of the central nervous system and cancer. The company is headquartered in Adelaide, South Australia, and has offices and research facilities in the United States and France. Bionomics was founded in 1998 by Dr. Deborah Rathjen, an experienced biotechnology manager and scientist. The company started as a spin-off from Flinders University in Adelaide, focusing initially on the discovery and development of drug candidates based on novel peptides. In 2002, Bionomics went public, gaining access to capital to expand its research activities and adjust its business strategy. Bionomics operates an integrated pharmaceutical model, ranging from the discovery and optimization of novel therapeutic targets and drugs to clinical development and market launch of pharmaceuticals. The company develops innovative technologies, including the MultiCore platform, to develop peptide-based drugs. Bionomics has two main divisions: CNS therapy and cancer therapy. The CNS therapy division focuses on the development of drugs for the treatment of central nervous system disorders, including schizophrenia, depression, anxiety disorders, neuropathic pain, spinal cord injuries, and other disorders. Bionomics is currently conducting clinical trials to evaluate the effectiveness of its leading drug candidates BN311 and BNO69 in the treatment of depression and anxiety disorders. Bionomics' cancer therapy division focuses on the discovery and development of drug candidates for the treatment of cancer. The company has identified a number of leading preclinical drug candidates based on novel targets, showing promising results in the treatment of breast, lung, ovarian, liver cancer, and other types of cancer. Bionomics has a range of products in development or in clinical stages. The company's leading product is BN311, a drug candidate for the treatment of depression based on Bionomics' MultiCore technology. BN311 has shown efficacy in preclinical studies in the treatment of depression and anxiety disorders and is currently being tested in a phase II clinical trial. BNO69 is another drug candidate from Bionomics based on the same technology. The candidate has been developed for the treatment of anxiety disorders and shows great promise. It has proven effective in preclinical studies and has the potential to revolutionize the treatment of anxiety disorders. The company is also developing drug candidates for the treatment of cancer, including BNC101, BNC105, BNC211, and BNC375. All of these drug candidates are based on novel targets and have shown promising results in preclinical studies. BNC375, a cancer immunotherapy, shows particularly promising results, and the company plans to conduct a phase I clinical trial to evaluate the efficacy of the drug in treating patients with advanced cancer. Overall, Bionomics Ltd is an emerging biopharmaceutical company specializing in the development of new and promising therapeutics for the treatment of diseases of the central nervous system and cancer. Bionomics has developed an integrated pharmaceutical model that supports innovation from discovery to commercialization and has a promising pipeline of drug candidates for the next generation of medications. Bionomics is one of the most popular companies on Eulerpool.

ROE Details

Decoding Bionomics's Return on Equity (ROE)

Bionomics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Bionomics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Bionomics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Bionomics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Bionomics stock

Return on Equity (ROE) of Bionomics is -38.23 % in 2026.

Return on Equity (ROE) of Bionomics changed from -18.27 % to -38.23 %, representing a 109.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Bionomics since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Bionomics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Bionomics

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Bionomics